Skip to main content

Table 4 Summary of clinical outcomes in patients who are human immunodeficiency virus positive and patients who are not human immunodeficiency virus positive referred for bariatric surgery

From: Bariatric surgery in individuals with human immunodeficiency virus and type 2 diabetes: a case series

  Baseline
BMI
%TWL
postop after 2 years
%EWL
postop after 2 years
HbA1c Complete remission of T2DM1
Preop Postop after 1 year
HIV case 1 (AGB) 46.6 24.4% 52.6% 41 33 No
HIV case 2 (SG) 50.7 25.2% 49.8% 35 32 Yes
HIV case 3 (SG) 47.8 14.1% 29.5% 128 90 No
AGB-non HIV (n = 61) 43.4 ± 6.2 14% ± 8% 34% ± 22% 60.6 ± 18.1 58.2 ± 13.5 5%
SG-non HIV (n = 56) 49.6 ± 10.7 22% ± 9% 42% ± 20% 59.5 ± 18.5 54.4 ± 18.1 27%
  1. AGB adjustable gastric band, BMI body mass index, EWL excessive weight loss, HbA1c glycated hemoglobin, HIV human immunodeficiency virus, SG sleeve gastrectomy, T2DM type 2 diabetes mellitus, TWL total weight loss. 1 according to American Diabetes Association criteria [8]. Data in non-HIV group were described as mean ± standard deviation